Yeda Research and Development Co. Ltd

What Yeda Research and Development Co. Ltd does

Yeda Research and Development Co. Ltd is the commercial arm of the Weizmann Institute of Science, founded in 1959 and headquartered in Rehovot, Israel. The company holds an exclusive agreement to commercialize intellectual property developed by Institute scientists, currently managing approximately 500 active unique patent families (with roughly 1,930 patent families registered cumulatively since inception) across therapeutics, diagnostics, medtech, agrobiotech, climate tech, quantum computing, and material science. Yeda has established nearly 100 spinoff companies over its history and lists more than 150 technologies available for commercialization across ten technology categories.

Yeda generates revenue through three primary mechanisms: licensing royalties on patented technologies (including FDA-approved blockbuster drugs such as Copaxone, Rebif, Erbitux, Vectibix, Portrazza, Humira, and the CAR-T therapy Yescarta), structured technology-transfer agreements with pharmaceutical and industrial partners (notably a multi-decade Merck framework agreement funding up to €1 million per year per research area), and equity stakes held in spinoff companies. Products based on Weizmann Institute research generated approximately $25 billion in sales in 2015 alone, and Yeda is reported to have produced the highest income per researcher of any academic technology transfer operation globally. Income is reinvested into basic research and science education at the Institute.

Yeda's customer base comprises pharmaceutical and biotech companies (Merck, Eli Lilly, Amgen, AstraZeneca via Immunai, Lysogene, Steba Biotech), industrial and technology firms (10x Genomics, Ginkgo Bioworks, 80 Acres Farms, Boehringer Ingelheim), and financial partners (Deerfield Management, YZi Labs). The organization is wholly owned by the Weizmann Institute of Science, governed by Israeli law, and operates with a small core staff (11–50 employees) supplemented by an extensive spinoff and licensee ecosystem. Recent strategic emphasis has been on emerging verticals — quantum computing (Quantum Art, Q-Factor), climate tech (Carbonade, NewCO2Fuels), AI-enabled drug discovery (Scala Biodesign), and optogenetics (Modulight) — alongside continued licensing of mature therapeutic assets.

Name

Yeda Research and Development Co. Ltd

Legal name

Yeda Research and Development Co. Ltd

Website

https://yedarnd.com

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

11–50 employees

Short description

Yeda Research and Development Co. Ltd is the commercial arm of the Weizmann Institute of Science, licensing intellectual property and forming spinoff companies based on Institute research. It manages approximately 500 active patent families and ~67 spinoffs across therapeutics, medtech, quantum computing, and agtech.

Ownership category

akta.pro rank

Product category

Technology Transfer Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Patent Owners & Lessors (6794), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

IP Management, Patents & Trademark Software (BPAEAPAN)

akta.pro secondary industry

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

Keywords

• Technology transfer services
• Intellectual property commercialization
• Patent licensing
• Spinoff company incubation
• Academic research commercialization

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Licensing Royalties: Yeda generates revenue through licensing agreements with pharmaceutical and biotech companies for technologies developed at the Weizmann Institute. This includes blockbuster drugs such as Copaxone, Rebif, Erbitux, Vectibix, Portrazza, Humira, and CAR-T cancer therapy Yescarta.
2. Technology Transfer Services: Commercialization of intellectual property through agreements with industry partners, including Merck's framework agreement funding research areas with up to €1 million per year over 3-year periods.
3. Equity Participation in Spinoffs: Yeda maintains equity stakes in spinoff companies established to commercialize Weizmann Institute technologies. The income generated serves to support further basic research and science education.

Distribution channels1 record

Marketing channels4 records

Core offering

Yeda Research and Development Co. Ltd is the commercial arm of the Weizmann Institute of Science, exclusively commercializing intellectual property developed by Institute scientists through licensing to industry partners and the formation of spinoff companies. The organization manages approximately 500 unique patent families across therapeutics, diagnostics, medtech, agrobiotech, quantum computing, climate tech, and material science, and has established nearly 100 spinoff companies since its founding in 1959. Yeda performs initial translational development work and then partners with industry for further commercialization, generating income that supports basic research and science education at the Weizmann Institute.

Product overview

Yeda Research and Development Co. Ltd is the commercial arm of the Weizmann Institute of Science, managing approximately 500 unique patent families and 67+ spinoff companies. Yeda does not operate a single unified product; instead, it commercializes technologies developed at the Institute through licensing agreements and the formation of spinoff companies. The portfolio spans multiple technology categories including Therapeutics (Phytolon, ImmunoBrain, Gnomica), MedTech & Digital Health (UltraSight, Sub-Q Bionics, C-Flow), DeepTech/Quantum Computing (Quantum Art, Q-Factor), Diagnostics (CLISEQ, ImmunArray with iCHIP), AgroTech (FreezeM, EcoPhage), ClimateTech (Carbonade, NewCO2Fuels), Material Science (Liposphere), and Research Tools (Scala Biodesign). These spinoffs operate as independent companies with their own products, while Yeda continues to manage new technology commercialization from the Institute's research labs.

Differentiator

Problem solved

Functional benefit

Products and services

• Yeda Technology Transfer Services Exclusive technology transfer and IP commercialization services for the Weizmann Institute of Science, managing approximately 500 unique patent families and ~67 spinoff companies. Services include identification of commercially promising research, initial translational development, patent prosecution, licensing to industry partners, and formation and equity participation in spinoff companies. Available to pharmaceutical, biotech, industrial, and investor partners globally.
• Licensable Technology Portfolio (150+ Technologies) Curated catalog of 150+ Weizmann Institute technologies available for licensing to industry partners, spanning therapeutics, diagnostics, medtech, agrobiotech, quantum computing, climate tech, material science, research tools, and software. Customers include pharmaceutical, biotech, and industrial companies seeking differentiated academic-derived IP.

Quantifiable outcome

• 25 billion dollars' worth of sales of Weizmann Institute-based products in 2015
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

16 partnerships are on record, tiered major, minor and core.

• Mayo ClinicmajorStrategic or Co-development Partner · 31 March 2026Mayo Clinic participated in Sub-Q Bionics $1.5M pre-seed round. Sub-Q is developing implantable lymphedema treatment technology based on Weizmann Institute research.
• 10x GenomicsmajorStrategic or Co-development Partner · 9 September 2025CLISEQ (Yeda spinoff), 10X Genomics and Weizmann Institute collaborating on single cell applications in hematology clinical diagnostics.
• Ginkgo BioworksmajorStrategic or Co-development Partner · 2 May 2025Phytolon (Yeda spinoff) and Ginkgo Bioworks announced successful completion of second development milestone in multi-product collaboration for natural food colours.
• 80 Acres FarmsmajorOthers · 10 February 202580 Acres Farms acquired Plantae Biosciences (Yeda spinoff), bringing innovative plant breeding technology to its technology-focused subsidiary Infinite Acres.
• MaianminorChannel Partner/ Reseller/ Distributor · 20 November 2024EcoPhage (Yeda spinoff) signed distribution agreement with Maian for Brazil to market GoldenEco bacteriophage-based bactericides.
• BlueQubitmajorStrategic or Co-development Partner · 14 August 2024BlueQubit and Quantum Art (Yeda spinoff) secured $2.2M BIRD Foundation grant to advance quantum machine learning and quantum processor configuration methods.
• eureKAREmajorStrategic or Co-development Partner · 22 February 2023Partnership with eureKARE to establish EonBio, focused on revolutionizing drug discovery with pioneering cell-free technology on a chip.
• AO (AO Research Institute Davos)majorStrategic or Co-development Partner · 24 November 2022Joint program with Liposphere Ltd (Yeda spinoff) for next-generation joint lubrication technology to alleviate osteoarthritis burden. Funded by AO's Development Incubator.
• RATION ConsortiummajorStrategic or Co-development Partner · 15 November 2022Metabolic Insights Ltd (Yeda subsidiary) joined RATION Consortium funded by EU Commission for improved risk assessment of biological pesticides over 4 years.
• Acceler8 Venture BuildermajorStrategic or Co-development Partner · 11 September 2022Partner in EICTransition project (eBeam4Therapy) funded by EU. Collaboration aims to revolutionize radiotherapy with very high energy electrons (VHEE) generated by laser plasma accelerators.
• XL-protein (Germany)majorStrategic or Co-development Partner · 1 December 2014Collaboration agreement for commercial exploitation of improved interferon molecule developed by Weizmann Institute scientists and XL-protein. Uses XL-protein's PAS technology to prolong drug life in blood. Could treat MS and other CNS diseases.
• Merck (Germany)coreStrategic or Co-development PartnerExtended partnership with new framework agreement spanning three years (with option for multiple successive 2-year extensions), funding each of two research areas with up to €1 million per year. Collaboration dates back to 1978 and has yielded Rebif (MS drug) and Erbitux (cancer drug). Focus areas include immuno-oncology, immunology, and oncology.
• ImmunaimajorStrategic or Co-development Partner$85M deal with AstraZeneca to develop new IBD drug target. Immunai is a Yeda portfolio company.
• Boehringer IngelheimcoreStrategic or Co-development PartnerCollaboration with BiomX (Yeda spinoff) to discover inflammatory bowel disease microbiome biomarkers.
• Monte Rosa TherapeuticsmajorStrategic or Co-development PartnerCollaboration between Yeda and Monte Rosa Therapeutics for drug development.
• Yeda's Spinoff CompaniescoreStrategic or Co-development PartnerNearly 100 spinoff companies established including: Phytolon, Quantum Art, Q-Factor, UltraSight, Renewal Bio, FreezeM, BiomX, Curesponse, DayTwo, ProFuse, Modulight Biotherapeutics, Scala Biodesign, Sub-Q Bionics, CLISEQ, Gnomica Biotherapy, Carbonade, and many others across therapeutics, diagnostics, medtech, agrobiotech, and quantum computing.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Oxford University Innovation: Technology transfer office of the University of Oxford, performing the same function as Yeda: commercializing university IP through licensing and spinoff formation, and participating in equity. Directly comparable in business model and mission, with a similarly broad life-sciences and physical-sciences research base.
• Cambridge Enterprise: University of Cambridge's technology transfer and commercialization arm. Operates the same licensing, equity and spinoff model as Yeda, with comparable deal flow in therapeutics, diagnostics and deeptech from a top-tier research institution.
• MIT Technology Licensing Office: MIT's central office responsible for managing and licensing intellectual property developed by MIT faculty. Closely comparable to Yeda as a leading US university TTO with a high commercialization output across biotech, software and physical sciences.
• Stanford Office of Technology Licensing (OTL): Stanford University's technology transfer office, famous for spinouts like Google and Genentech. Directly comparable to Yeda in mission, IP licensing model, and high commercialization rate from a world-leading research base.
• Columbia Technology Ventures: Columbia University's tech transfer office managing invention disclosures, patent prosecution, licensing and startup formation. Comparable to Yeda as a large US university TTO with a strong therapeutics and engineering pipeline.
• Max Planck Innovation: Technology transfer arm of the Max Planck Society in Germany. Closely parallels Yeda's model — dedicated central entity responsible for licensing IP and creating spinoffs from a top-ranked basic-research institution with strong life-sciences output.
• Harvard Office of Technology Development (OTD): Harvard University's technology transfer office. Directly comparable to Yeda in licensing life-sciences and biotech IP from a top global research institution, including active spinoff formation and equity participation.
• Imperial College Innovations: Imperial College London's technology transfer function, focused on commercializing research outputs in engineering, medtech, biotech and physical sciences. Comparable to Yeda in scale, sector mix and licensing-plus-spinoff model.

Regional players

• Technion Technology Transfer (T3): Technology transfer arm of the Technion – Israel Institute of Technology. Directly comparable in mission and operating model, but serving a different Israeli institution, so it is best characterized as a regional peer rather than a direct competitor.

Broad incumbents

• Bayer Pharmaceuticals (Pharma Licensing): A global pharmaceutical major that both in-licenses external IP (including academic discoveries) and develops its own pipeline. Overlaps with Yeda on the demand side — a typical partner/customer profile for Yeda-licensed technologies such as Rebif/Erbitux via Merck and Portrazza via Lilly — and therefore a relevant comparator for the buyer side of Yeda's model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/YedaWeizmann
• YouTubeyoutube.com/channel/UCyc8-Bn3SxqZH-gJgxBhgVA
• Facebookfacebook.com/yeda.rnd
• LinkedInlinkedin.com/company/yeda-weizmann
• Instagraminstagram.com/yeda.weizmann

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yeda Research and Development Co. Ltd